Filtered By:
Cancer: Leukemia
Drug: Nilotinib
This page shows you your search results in order of date.
Order by Relevance | Date
Total 178 results found since Jan 2013.
IL-33-ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways
Sci Signal. 2023 Aug 29;16(800):eadd7705. doi: 10.1126/scisignal.add7705. Epub 2023 Aug 29.ABSTRACTCell stemness is characterized by quiescence, pluripotency, and long-term self-renewal capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in patients with chronic and acute myeloid leukemia (CML and AML). However, the same signaling pathways frequently support stemness in both LSCs and normal hematopoietic stem cells (HSCs), making LSCs difficult to therapeutically target. In cell lines and patient samples, we found that interleukin-33 (IL-33) signaling promoted stemness only in leukemia c...
Source: Science Signaling - August 29, 2023 Category: Biomedical Science Authors: Pascal Naef Ramin Radpour Carla A Jaeger-Ruckstuhl Nils Bodmer Gabriela M Baerlocher Hartmut Doehner Konstanze Doehner Carsten Riether Adrian F Ochsenbein Source Type: research
Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National PopulationBased Cohort Study
CONCLUSION: The findings of this study indicate that nilotinib treatment is associated with increased risks of diabetes and hyperlipidemia, with hyperlipidemia being the most significant risk for CVDs. Therefore, we recommend that CML patients receiving nilotinib should undergo screening for diabetes and hyperlipidemia prior to initiating TKI treatment. Additionally, regular monitoring of lipid profiles during TKI therapy and implementing effective management strategies to control hyperlipidemia are crucial.PMID:37561957 | DOI:10.1093/oncolo/oyad225
Source: The Oncologist - August 10, 2023 Category: Cancer & Oncology Authors: Cih-En Huang Kuan-Der Lee Jung-Jung Chang Huey-En Tzeng Shih-Hao Huang Lennex Hsueh-Lin Yu Min-Chi Chen Source Type: research
Nilotinib cause moyamoya disease in the treatment of chronic myelogenous leukemia in chronic phase: A case report
Asian J Surg. 2023 May 1:S1015-9584(23)00521-3. doi: 10.1016/j.asjsur.2023.04.020. Online ahead of print.NO ABSTRACTPMID:37137777 | DOI:10.1016/j.asjsur.2023.04.020
Source: Asian Journal of Surgery - May 3, 2023 Category: Surgery Authors: Jin-Ping Liang Rui-Hua Mi Lin Chen Xu-Dong Wei Source Type: research
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects
In this study, we retrospectively analyzed 178 patients with newly diagnosed CML-CP who were treated with dasatinib or nilotinib, focusing on age and dose effects. Efficacy as measured by cumulative major molecular response (MMR) and molecular response 4.5 rates did not differ significantly between the younger group and elderly group. Elderly patients who started nilotinib at a reduced dose had similar or better efficacy outcomes (including cumulative MMR and continuation ratios) than other groups, and elderly patients who started dasatinib at a reduced dose had the lowest MMR ratio and longest MMR duration. Effects of dos...
Source: International Journal of Hematology - May 2, 2023 Category: Hematology Authors: Michihide Tokuhira Yuta Kimura Takayuki Tabayashi Naoki Watanabe Shun Tsuchiya Tomoiku Takaku Noriyoshi Iriyama Eriko Sato Tomonori Nakazato Toru Mitsumori Maho Ishikawa Hiroyuki Fujita Masahiro Kizaki Miki Ando Yoshihiro Hatta Eisaku Iwanaga Tatsuya Kawa Source Type: research
Tyrosine Kinase Inhibitor-associated Cerebral Arterial Occlusive Disease Treated with High-flow Bypass Surgery: A Case Report
NMC Case Rep J. 2023 Mar 24;10:61-66. doi: 10.2176/jns-nmc.2022-0298. eCollection 2023.ABSTRACTNilotinib, one of the tyrosine kinase inhibitors, has been used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Nilotinib-associated cerebral arterial occlusive disease, which is treated with medicine with/without bypass surgery or stenting, has been sporadically reported to occur. The mechanism of the nilotinib-associated cerebral disease has not been clarified and is still controversial. Here we present the case of a 39-year-old woman with Ph+ ALL treated with...
Source: Atherosclerosis - April 17, 2023 Category: Cardiology Authors: Yurie Rai Takayuki Hara Source Type: research
